• 1
    Joint UN Programme on HIV/AIDS 2010 Global report. Available at: full_en.pdf. Accessed on April 1, 2012.
  • 2
    Weber R, Sabin CA, Friis-Møller N, Reiss P, El-Sadr WM, Kirk O, et al. Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. Arch Intern Med 2006; 166: 1632-1641.
  • 3
    Ruppik M, Ledergerber B, Rickenbach M, Furrer H, Battegay M, Cavassini M, et al. Changing Patterns of Causes of Death: SHCS, 2005 to 2009. [Abstract] 18th Conference on Retroviruses and Opportunistic Infections, Boston, MA, February 27-March 2, 2011. Abstract no.: 789.
  • 4
    Ioannou GN, Bryson CL, Weiss NS, Miller R, Scott JD, Boyko EJ. The prevalence of cirrhosis and hepatocellular carcinoma in patients with HIV infection. Hepatology 2013; 58: 249-257.
  • 5
    Mallolas J, Pol S, Rivero A, Fainboim H, Cooper C, Slim J, et al. Boceprevir plus pegfinterferon/ribavirin for the treatment of HCV/HIV co-infected patients: end of treatment (week 48) interim results. [Abstract]. J Hepatol 2012; Suppl 1: S22.
  • 6
    Dieterich D, Soriano V, Sherman K, Girard P-M, Rockstroh J, Adiwijaya B, et al. Telaprevir in combination with pegylated interferon-a-2a+RBV in HCV/HIV-co-infected patients: a 24-week treatment interim analysis. [Abstract]. 19th Conference On Retroviruses and Opportunistic Infections, Seattle, WA, March 5-8, 2012. Abstract no.: 46.
  • 7
    Chung RT. A watershed moment in the treatment of hepatitis C. N Engl J Med 2012; 366: 273-275.
  • 8
    Spradling PR, Richardson JT, Buchacz K, Moorman AC, Brooks JT; HIV Outpatient Study (HOPS) Investigators. Prevalence of chronic hepatitis B virus infection among patients in the HIV Outpatient Study, 1996-2007. J Viral Hepat 2010; 17: 879-886.
  • 9
    Kellerman SE, Hanson DL, McNaghten AD, Fleming PL. Prevalence of chronic hepatitis B and incidence of acute hepatitis B infection in human immunodeficiency virus-infected subjects. J Infect Dis 2003; 188: 571-577.
  • 10
    Puoti M, Moioli MC, Rossotti R, Travi G. The burden of liver disease in HIV. Semin Liver Dis 2012 (In press).
  • 11
    Puoti M, Cozzi-Lepri A, Paraninfo G, Arici C, Moller NF, Lundgren JD, et al. Impact of lamivudine on the risk of liver-related death in 2,041 HBsAg- and HIV-positive individuals: results from an inter-cohort analysis. Antivir Ther 2006; 11: 567-574.
  • 12
    Cooper RD, Wiebe N, Smith N, Keiser P, Naicker S, Tonelli M. Systematic review and meta-analysis: renal safety of tenofovir disoproxil fumarate in HIV-infected patients. Clin Infect Dis 2010; 51: 496-505.
  • 13
    Dore GJ, Soriano V, Rockstroh J, Kupfer B, Tedaldi E, Peters L, et al. Frequent hepatitis B virus rebound among HIV-hepatitis B virus-coinfected patients following antiretroviral therapy interruption. AIDS 2010; 24: 857-865.
  • 14
    Capeau J, Bouteloup V, Katlama C, Bastard JP, Guiyedi V, Salmon-Ceron D, et al. Ten-year diabetes incidence in 1046 HIV-infected patients started on a combination antiretroviral treatment. AIDS 2012; 26: 303-314.
  • 15
    Mocroft A, Soriano V, Rockstroh J, Reiss P, Kirk O, de Wit S, et al. Is there evidence for an increase in the death rate from liver-related disease in patients with HIV? AIDS 2005; 19: 2117-2125.